Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-05-21

FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SUSVIMO (ranibizumab) from Genentech, expanding the regulatory approval for this port delivery system delivering…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUSVIMO (Ranibizumab)

Snippet

SUPPL AP for SUSVIMO (RANIBIZUMAB)